Home › Targets › SIGMAR1
Radioligand therapy target profile

SIGMAR1: IHC Expression in Cancer and Radioligand Target Profile

sigma non-opioid intracellular receptor 1 · Ensembl ENSG00000147955 · Data updated 2026-11-01

SIGMAR1, sigma non-opioid intracellular receptor 1, is a cell-surface protein (membrane receptor). In Human Protein Atlas immunohistochemistry, SIGMAR1 staining is highest in thyroid cancer (100% of samples positive), colorectal cancer (100% of samples positive) and liver cancer (91% of samples positive). Evidence on whether SIGMAR1 internalizes is mixed. Clinical status: FDA-approved drug (any modality).

Is SIGMAR1 the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.

Analyze SIGMAR1 free
LocalizationCell-Surface
Top cancer (IHC)Thyroid Cancer
InternalizationUncertain
Clinical stageFDA-approved drug (any modality)
Active trialsSee ClinicalTrials.gov
Cancer association (Open Targets)0.13

Is SIGMAR1 a good radioligand therapy target?

Scored against the six criteria that decide whether a protein can become a radioligand therapy:

SIGMAR1 IHC staining by cancer type

Protein expression of SIGMAR1 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.

Cancer typeIHC scoreLevel% positive
Thyroid Cancer1.00High100%
Colorectal Cancer0.75High100%
Liver Cancer0.73High91%
Cervical Cancer0.64High100%
Ovarian Cancer0.61High100%
Bladder Cancer0.55High82%
Breast Cancer0.50Medium100%
Endometrial Cancer0.50Medium83%
Melanoma0.44Medium83%
Skin Cancer0.42Medium91%
Pancreatic Cancer0.42Medium92%
Head and Neck Cancer0.42Medium75%
Neuroendocrine Tumors0.42Medium75%
Lung Cancer0.42Medium75%
Gastric Cancer0.37Medium70%
Glioma0.33Medium75%
Prostate Cancer0.31Medium58%
Lymphoma0.25Medium58%
Kidney Cancer0.19Low50%
Testicular Cancer0.04Low11%

Is SIGMAR1 internalized?

Uncertain. Insufficient literature found.

SIGMAR1 clinical trials

FDA-approved drug (any modality). Nuclens hasn't indexed trials for SIGMAR1 yet. Search ClinicalTrials.gov for SIGMAR1 trials.

SIGMAR1 normal tissue expression

Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See SIGMAR1 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.

SIGMAR1 gene essentiality (DepMap)

CRISPR knockout effect across 1258 cancer cell lines: -0.21 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.

Related thyroid cancer radioligand targets

c-MET (MET) · HER3 (ERBB3) · SSTR2 · EPCAM · EGFR · ITGAV · STEAP2 · Nectin-4 (NECTIN4)

See all radioligand therapy targets in thyroid cancer.

See how SIGMAR1 ranks against 15,000 targets for your indication.

Analyze SIGMAR1 free

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Is SIGMAR1 the right target for your program? · 5 free analyses, no card Analyze SIGMAR1 free